Pre-treatment with 3,4-methylenedioxymethamphetamine (MDMA) causes long-lasting changes in 5-HT2A receptor-mediated glucose utilization in the rat brain

J Psychopharmacol. 2006 Mar;20(2):272-80. doi: 10.1177/0269881106059583.

Abstract

The current study examined the long-term effect of brief exposure to 3,4-methylenedioxymethamphetamine (MDMA) on local cerebral glucose utilization (LCGU) in specific brain regions immediately following administration of the 5-HT2A/2C receptor agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). Wistar rats (post-natal day (PND) 28, n = 24) were administered MDMA (5 mg/kg, i.p.) or saline (1 ml/kg, i.p.) four times daily for 2 consecutive days and core body temperature was recorded. Fifty-five days later and 10 min following injection of DOI (1 mg/kg, i.p.) or saline, LCGU was measured using the [14C]2-deoxyglucose (2-DG) technique. In the 4 hours following the initial injection (PND 28), MDMA-treated rats exhibited significant hyperthermia compared with saline-treated controls (p < 0.05-0.01). Eight weeks later, immediately following DOI challenge, LCGU was significantly elevated (an increase of 47%, p < 0.05) in the nucleus accumbens of MDMA/DOI pretreated rats, compared with that in MDMA/saline pre-treated controls. A similar trend was observed in other areas such as the lateral habenula, somatosensory cortex and hippocampal regions (percentage changes of 27-41%), but these did not reach significance. Blood glucose levels were significantly elevated in both groups of DOI-treated rats (p < 0.05-0.01). Thus, brief exposure of young rats to an MDMA regimen previously shown to cause anxiety-like behaviour and modest serotonergic neurotoxicity (Bull et al., 2004) increased DOI-induced energy metabolism in the nucleus accumbens and tended to increase metabolism in other brain regions, including the hippocampus, consistent with the induction of long-term brain region specific changes in synaptic plasticity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autoradiography
  • Blood Glucose / metabolism*
  • Brain / drug effects*
  • Deoxyglucose / metabolism
  • Energy Metabolism / drug effects*
  • Hallucinogens / toxicity*
  • Injections, Intraperitoneal
  • Male
  • N-Methyl-3,4-methylenedioxyamphetamine / toxicity*
  • Nucleus Accumbens / drug effects
  • Premedication
  • Rats
  • Rats, Wistar
  • Receptor, Serotonin, 5-HT2A / drug effects*
  • Serotonin Agents / toxicity*

Substances

  • Blood Glucose
  • Hallucinogens
  • Receptor, Serotonin, 5-HT2A
  • Serotonin Agents
  • Deoxyglucose
  • N-Methyl-3,4-methylenedioxyamphetamine